Copyright
©The Author(s) 2022.
World J Clin Cases. Apr 16, 2022; 10(11): 3449-3460
Published online Apr 16, 2022. doi: 10.12998/wjcc.v10.i11.3449
Published online Apr 16, 2022. doi: 10.12998/wjcc.v10.i11.3449
No. | Ref. | Country or region | Study design | Groups investigated | Age | Diagnostic criteria | Assessment scales | Adjusted variables | MCI (%) | Dementia (%) | NOS quality score |
1 | Mermit Çilingir et al[17], 2020 | Turkey | Case Control | COPD-E (n = 30); COPD-S (n = 54); Control (n = 37) | COPD-E-71.8 ± 12.3; COPD-S- 62 ± 10.2; Control-65.9 ± 12.8 | GOLD | MMSE; RCS | NA | NA | NA | 7 |
2 | Xie et al[18], 2019 | China | Prospective Cohort | COPD (n = 515); No COPD (n = 4220) | COPD-82.9 ± 9.7 | GOLD | MMSE | Age, gender, marital status, education level, alcohol drinking, current exercise, BMI, baseline prevalence of HTN, DM, and stroke | 18.8; 14.6 | 2.9; 1.6 | 8 |
3 | Samareh Fekri et al[19], 2017 | Iran | Case Control | COPD (n = 87); Control (n = 60) | COPD-60.4 ± 9.8; Control-58.1 ± 9.8 | GOLD | MMSE | Age and sex | 51.7; 36.6 | NA | 7 |
4 | Gupta et al[20], 2013 | India | Case Control | COPD-(n = 40); Control (n = 40) | COPD-57.2 ± 9.1; Control-56.9 ± 9.2 | GOLD | MMSE | Age | NA | NA | 5 |
5 | Li et al[21], 2013 | China | Case Control | Mild COPD-(n = 27); Severe COPD-(n = 35); Control (n = 27) | Mild COPD-70.4 ± 7.7; Severe COPD-68.2 ± 7.8; Control-66.2 ± 7.1 | GOLD | MMSE | Age, sex, education level, BMI, smoking status, and CVD | NA | NA | 6 |
6 | Li et al[22], 2013 | China | Case Control | Mild COPD-(n = 37); Severe COPD-(n = 48); Control (n = 37) | Mild COPD-69.2 ± 8.1; Severe COPD-67.6 ± 7.6; Control-66.5 ± 6.9 | GOLD | MMSE | Age, sex, education level, BMI, smoking status, and CVD | NA | NA | 8 |
7 | Liao et al[23], 2015 | Taiwan | Retrospective Cohort | COPD (n = 20492); No COPD (n = 40765) | COPD-68.2 ± 12.4; No COPD-67 ± 12.5 | ICD-9CM | NA | Age and sex | NA | 13.29.11 | 7 |
8 | Martinez et al[24], 2014 | Michigan | Cross-sectional | COPD (n = 1812); No COPD (n = 15723) | COPD-70.3 ± 9.0; No COPD-68.7 ± 9.9 | GOLD | ADL | Baseline cognition | 16.5; 12.4 | 3.9; 3.1 | 8 |
9 | Dal Negro et al[25], 2015 | Italy | Cross-sectional | COPD with LTOT (n = 73); COPD without LTOT (n = 73) | COPD with LTOT-70.9 ± 8.9; No COPD with LTOT-71.2 ± 9.1 | GOLD | MMSEMRC; CAT | Age, gender, smoking history, BMI, dyspnoea score, ABG, and lung function | 32.8 | NA | 6 |
10 | Singh et al[26], 2013 | United States | Cross-sectional | COPD (n = 288); No COPD (n = 1639) | MCI-82.7 ± 11.2; Normal Cognition-79.7 ± 12.5 | Standard criteria | BDI; CDR | BDI-II Depression, history of stroke, APOEe4 genotype, DM, HTN, CAD, and BMI | 14.6; 27.1 | NA | 7 |
11 | Singh et al[3], 2014 | United States | Cross-sectional | Total COPD (n = 1425); COPD (n = 171); No COPD (n = 1254) | COPD-80.8 ± 7.5; No COPD-79.1 ± 7.5 | Standard criteria | BDI | BDI-II depression, history of stroke, APOEe4 genotype, smoking, DM, HTN, CAD, z-scores, and BMI | NA | NA | 7 |
12 | Lutsey et al[27], 2019 | United States | Prospective Cohort | COPD (n = 2490); No COPD (n = 6108) | COPD-55.1 ± 5.8; No COPD-53.9 ± 5.7 | GOLD | NA | Age, sex, education level, race, center, cigarette smoking and pack-years of smoking, physical activity, BMI, systolic BP, BP medication use, diabetes, HDL, LDL lipid-lowering medications, CAD, heart failure, stroke, apolipoprotein E genotype, and fibrinogen | NA | NA | 6 |
13 | Siraj et al[28], 2020 | United Kingdom | Case Control | COPD (n = 64397); No COPD (n = 243420) | COPD-66.4 ± 10.9; No COPD-65.7 ± 11 | Standard criteria | NA | Age, sex, GP, BMI, smoking status, modified CCI, CV disease, corticosteroid use, and socioeconomic class | NA | NA | 7 |
14 | Villeneuve et al[29], 2012 | Canada | Case Control | Total COPD (n = 45); Control (n = 50) | COPD-68.4 ± 8.7; Control-67.4 ± 8.7 | GOLD | MMSE; MoCA | Age and education | 36.0; 12.0 | NA | 5 |
15 | Yeh et al[30], 2018 | Taiwan | Prospective Cohort | COPD (n = 10260); No COPD (n = 20513) | COPD-65.6 ± 11.8; No COPD-65.5 ± 11.9 | GOLD | NA | Age, sex, each comorbidity, inhaled corticosteroid, and oral steroids | NA | 11.1; 8.81 | 4 |
16 | Ozge et al[31], 2006 | Turkey | Prospective cohort | COPD (n = 54); Control (n = 24) | COPD-64.6 ± 8.5; Control-62.4 ± 8.4 | GOLD | MMSE,BDS, CDR, IADL | Age and sex | NA | NA | 6 |
17 | Favalli et al[32], 2008 | Turkey | Cross-sectional | COPD (n = 21); Control (n = 20) | COPD-74.6 ± 5.4; Control-73.7 ± 4.5 | GOLD | MMSE; GDS | NA | NA | NA | 5 |
18 | Liao et al[10], 2015 | Taiwan | Retrospective Cohort | COPD (n = 8640); No COPD (n = 17280) | COPD-68.7 ± 10.7; No COPD-68.7 ± 10.7 | ICD-9CM | Self-administered questionnaire | Age and sex | NA | 5.22; 7.06 | 6 |
19 | Thakur et al[33], 2010 | United States | Retrospective Cohort | COPD (n = 1202); Control (n = 302) | COPD-58.2 ± 6.2; Control-58.5 ± 6.2 | ICD-9CM | MRC; BODE index; MMSE | Age, sex, race, educational attainment, and smoking history | 5.5; 2.0 | NA | 7 |
20 | Zhou et al[34], 2012 | China | Case Control | COPD (n = 110); Control (n = 110) | COPD-80.9 ± 1.7; Control-80.8 ± 1.5 | GOLD | CDR; MMSE | Age and education | NA | NA | 6 |
21 | Dodd et al[4], 2013 | United Kingdom | Cross-sectional | COPD-E (n = 30); COPD-S (n = 50); Control (n = 30) | COPD-E-70 ± 11; COPD-S-69 ± 8; Control-65 ± 8 | GOLD | MMSE | Age | NA | NA | 7 |
22 | Isoaho et al[35], 1996 | Finland | Case Control | COPD (n = 81); Control (n = 245) | COPD-70.4 ± 4.8; Control-71.3 ± 5.9 | GOLD | MMSE | Age and sex | 17.0; 13.0 | 7.1; 3.2 | 6 |
23 | Lima et al[36], 2007 | Brazil | Cross-sectional | COPD (n = 30); Control (n = 34) | COPD-65 ± 8; Control-66 ± 8 | GOLD | MMSE; DSM-IV | NA | NA | NA | 5 |
24 | Ozyemisci-Taskiran et al[37], 2015 | Turkey | Cross-sectional | COPD-E (n = 133); COPD-S (n = 34); Control (n = 34) | COPD-E-69.3 ± 8.9; COPD-S-67.5 ± 8.9; Control-68.3 ± 8.8 | GOLD | MMSE; HAD; BODE | Age and sex | 22.6 | NA | 6 |
25 | Salik et al[38], 2007 | Turkey | Cross-sectional | COPD (n = 32); Control (n = 26) | COPD-66.7 ± 2.5; Control-65.7 ± 7.3 | GOLD | MMSE; MCS | NA | NA | NA | 5 |
26 | Sarınç Ulaşlı et al[39], 2013 | Turkey | Case Control | COPD (n = 112); Control (n = 44) | COPD-65 ± 7.6; Control-64 ± 9 | GOLD | MMSE | Age and sex | NA | NA | 5 |
27 | Tomruk et al[40], 2015 | Turkey | Cross-sectional | COPD (n = 35); Control (n = 36) | COPD-62.9 ± 6.3; Control-60.8 ± 6.2 | GOLD | MMSE | Age | NA | NA | 4 |
- Citation: Zhao LY, Zhou XL. Association of chronic obstructive pulmonary disease with mild cognitive impairment and dementia risk: A systematic review and meta-analysis. World J Clin Cases 2022; 10(11): 3449-3460
- URL: https://www.wjgnet.com/2307-8960/full/v10/i11/3449.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v10.i11.3449